Targets readouts from nine ongoing Phase 2 and Phase 3 clinical studies in its oncology pipeline, including three Phase 3 programs for intismeran autogene Further improves 2026 and 2027 expected GAAP ...
On May 6, 2026, Moderna’s board amended its bylaws to require Securities Act of 1933 lawsuits be filed exclusively in US ...
Hosted on MSN
Moderna gears up for Q4 print; here are the recent forecast changes from Wall Street's most accurate analysts
Moderna, Inc. MRNA will release earnings for its fourth quarter before the opening bell on Friday, Feb. 13. Analysts expect the Cambridge, Massachusetts-based company to report a quarterly loss at ...
Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026 Expects to expand seasonal vaccine franchise from three to up to six approved products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results